Treatment of adults with recurrent malignant glioma

Expert Review of Neurotherapeutics

Volumn 5, Issue 4, 2005, Pages 509-514

  Nabors, L Burt ^a   Fiveash, John ^a  

^a The University of Alabama at Birmingham   (United States)

Author keywords

Chemotherapy; Glioma; Magnetic resonance imaging; Radiation therapy; Surgery

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; CARBAMAZEPINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; ERLOTINIB; ETOPOSIDE; GEFITINIB; IMATINIB; IRINOTECAN; LOMUSTINE; NITROSOUREA; PHENOBARBITAL; PHENYTOIN; PLATINUM DERIVATIVE; PROCARBAZINE; TEMOZOLOMIDE; THALIDOMIDE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CYTOTOXICITY; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; FATIGUE; GAMMA KNIFE RADIOSURGERY; GLIOBLASTOMA; HUMAN; LUNG INJURY; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PROGNOSIS; REVIEW; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; GLIOMA; HUMANS; RADIOSURGERY; RECURRENCE;

EID: 22544431638     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.5.4.509     Document Type: Review

References (37)

1. Wrensch M, Minn Y, Chew T, Bondy M, Berger MS. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro-Oncology 4, 278-299 (2002).
2. Lamborn K, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro-Oncol. 6, 227-235 (2004).
3. Aldape KD, Okcu MF, Bondy M, Wrensch M. Molecular epidemiology of glioblastoma. Cancer J. 9, 99-106 (2003).
4. Ino Y, Betensky RA, Zlatescu MC et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin. Cancer Res. 7, 839-845 (2001).
5. Bondy M, Wiencke J, Wrensch M, Kyritsis AP. Genetics of primary brain tumors: a review. J. Neurooncol. 18, 69-81 (1994).
6. Laws ER, Parney IF, Huang W et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J. Neurosurg. 99, 467-473 (2003).
7. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359, 1011-1018 (2002).
8. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
9. Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol. 17, 2572-2578 (1999).
10. Chang SM, Parney IF, McDermott M et al. Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcomes Project. J. Neurosurg. 98, 1175-1181 (2003).
11. Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345, 1008-1012 (1995).
12. Li X, Jin H, Oh J, Chang SM, Nelson SJ. Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas. NMR Biomed. 17, 10-20 (2004).
13. Henson JW, Gaviani P, Gonzalez RG. MRI in treatment of adult gliomas. Lancet Oncol. 6, 167-175 (2005).
14. Atlas SW, Howard RS, Maldjian J et al. Functional magnetic resonance imaging of regional brain activity in patients with intracerebral gliomas: findings and implications for clinical management. Neurosurgery 38, 329-338 (1996).
15. Wirtz CR, Knauth M, Staubert A et al. Clinical evaluation and follow-up results for intraoperative magnetic resonance imaging in neurosurgery. Neurosurgery 46, 1112-1120 (2000).
16. Nimsky C, Fujita A, Ganslandt O, Von Keller B, Fahlbusch R. Volumetric assessment of glioma removal by intraoperative high-field magnetic resonance imaging. Neurosurgery 55, 358-370 (2004).
17. Kim HK, Thorton AF, Greenberg HS et al. Results of re-irradiation of primary intracranial neoplasms with three-dimensional conformal therapy. Am. J. Clin. Oncol. 20, 358-363 (1997).
18. Hudes RS, Corn BW, Werner-Wasik M et al. A Phase I dose escalation study of hypofractionated sterotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int. J. Radiat. Oncol. Biol. Phys. 43(2), 293-298 (1999).
19. Loeffler JS, Alexander E, Hochberg FH. Clinical patterns of failure following stereotactic interstitial irradiation for malignant glioma. Int. J. Radiat. Oncol. Biol. Phys. 19(6), 1455-1462 (1990).
20. Larson DA, Suplica JM, Chang SM et al. Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neuro-Oncology 6(2), 119-126 (2004).
21. 125I radiation source (Gliasite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial. J. Neurosurg. 99(2), 297-303 (2003).
22. Gabayan AJ, Sanan A, Bastin K et al. Gliasite radiotherapy system for treatment of recurrent malignant glioma: a multi-institutional analysis. Int. J. Radiat. Oncol. Biol. Phys. 60, S258 (2004).
23. Shaw EG, Scott C, Souhami L et al. Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: initial report of radiation therapy oncology group protocol (90-05). Int. J. Radiat. Oncol. Biol. Phys. 34(3), 647-654 (1996).
24. Shaw EG, Scott C, Souhami L. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and metastases: final report of RTOG protocol 90-05. Int. J. Radiat. Oncol. Biol. Phys. 47, 291-298 (2000).
25. Larson DA, Gutin PH, McDermott M et al. Gamma knife for glioma: selection factors and survival. Int. J. Radiat. Oncol. Biol. Phys. 36(5), 1045-1053 (1996).
26. Yung A, Prados M, Yaya-Tur R et al. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J. Clin. Oncol. 17, 2762-2771 (1999).
27. Walker MD, Aexander E, Hunt WE et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative clinical trial. J. Neurosurg. 49, 333-343 (1978).
28. Walker MD, Green SB, Byar DP et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl. J. Med. 303, 1323-1329 (1980).
29. Fine HA, Wen PY, Maher EA et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J. Clin. Oncol. 21, 2299-2304 (2003).
30. Tanizawa A, Fujimori A, Fujimori Y et al. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl Cancer Inst. 86, 836-842 (1994).
31. Friedman HS, Petros WP, Friedman A et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol. 17, 1516-1525 (1999).
32. Buckner JC, Reid JM, Wright K et al. Irinotecan in the treatment of glioma patients. Cancer 97(Suppl 9), 2352-2358 (2003).
33. Gilbert MR, Supko JG, Batchelor T et al. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin. Cancer Res. 9, 2940-2949 (2003).
34. Yung WKA, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma: a Phase II study. J. Clin. Oncol. 9, 860-864 (1991).
35. Silvani A, Eoli M, Salmaggi A et al. Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. J. Neurooncol. 66, 203-208 (2004).
36. Franceschi E, Cavallo G, Scopece L et al. Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. Br. J. Cancer 13, 1038-1044 (2004).
37. Jeremic B, Grujicic D, Jevremovic S et al. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a Phase II study. J. Clin. Oncol. 10, 1074-1077 (1992).